VistaGen Therapeutics, Inc. (VTGN) News

VistaGen Therapeutics, Inc. (VTGN): $5.36

0.06 (+1.13%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add VTGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#207 of 359

in industry

Filter VTGN News Items

VTGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VTGN News Highlights

  • For VTGN, its 30 day story count is now at 2.
  • Over the past 7 days, the trend for VTGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about VTGN are CNS and TSE.

Latest VTGN News From Around the Web

Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.

The 7 Best Short-Squeeze Stocks to Buy Now: September 2023

Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong.

Josh Enomoto on InvestorPlace | September 21, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

SOUTH SAN FRANCISCO, Calif., September 12, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of p

Yahoo | September 12, 2023

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

SOUTH SAN FRANCISCO, Calif. & TOKYO, September 05, 2023--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. ("Fuji") (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women’s healthcare and acute medical care, today announced they have entered into a tim

Yahoo | September 5, 2023

Vistagen Appoints Cindy Anderson as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., August 22, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year.

Yahoo | August 22, 2023

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023. I would now like to turn the conference over to Mark […]

Yahoo | August 15, 2023

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Yahoo | August 11, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning!

William White on InvestorPlace | August 10, 2023

Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., August 10, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 first quarter ended June 30, 2023.

Yahoo | August 10, 2023

COMMODORE CAPITAL LP Acquires New Stake in Vistagen Therapeutics Inc

Firm real-time pick highlight

Yahoo | August 10, 2023

AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

AffaMed Therapeutics ("AffaMed") announced today that its partner Vistagen Therapeutics ('Vistagen' - NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, reported positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults diagnosed with social anxiety disor

Yahoo | August 10, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!